Current knowledge on Multiple Sclerosis (MS) etiopathogenesis encompasses complex
interactions between the host's genetic background and several environmental factors that …

Background COVID-19 may spread through various ways ranging from asymptomatic to
severe forms, until respiratory failure, critical conditions and death occurs. There is a …

The availability of vaccines against the severe acute respiratory syndrome coronavirus 2
(SARS-CoV-2), provides hope towards mitigation of the coronavirus disease 2019 (COVID …

Background COVID-19 vaccination is recommended for patients with multiple sclerosis
(pwMS), while disease-modifying therapies (DMTs) may influence the efficacy of SARS-CoV …

Background and Objectives It is unclear how multiple sclerosis (MS) affects the severity of
COVID-19. The aim of this study is to compare COVID-19–related outcomes collected in an …

Background and purpose Although the COVID‐19 vaccines are currently recommended for
people with multiple sclerosis (MS), the fact that they were not specifically tested in people …

Objective: To describe a temporal association between COVID-19 vaccine administration
and multiple sclerosis (MS) relapses. Methods: This case series study was collected in four …

Background: Ozanimod, an oral sphingosine 1-phosphate receptor 1 and 5 modulator, is
approved in multiple countries for treatment of relapsing forms of MS. Objective: To …

Infection of the CNS with the SARS-CoV-2 can occur via different routes and results in para-
or post-infectious manifestations with a variety of neurological symptoms. In patients with …

Myelin oligodendrocyte glycoprotein (MOG) antibody-associated disorder (MOGAD) is a
newly identified autoimmune demyelinating disorder that is often associated with acute …